The S-3 enables selling stockholders to sell shares into the market, creating potential overhang. Monitor trading volumes and any 424 prospectus supplements for actual sales. The company's cash position of $53.3M provides runway into 2029 per the prior 8-K summary.
Drugs in focus
EQ drug pipeline →EQ504
● Neutral Named in this S-3- Impact
- Phase
- Phase 1
- Time to market
- Unknown — the drug is in Phase 1 healthy-volunteer testing. If successful through Phase 2 and Phase 3, potential approval would be several years away (likely 2029-2031 at the earliest).
- Next catalyst
- None dated
What to watchThe next hard catalyst is topline Phase 1 proof-of-mechanism data in Q2 2027 (~6 months from now). Positive data showing AhR target engagement and a clean safety profile in healthy volunteers would validate the mechanism and support advancement into a Phase 2 proof-of-concept study in ulcerative colitis patients in H2 2027. Negative safety signals or failure to demonstrate target engagement would severely damage the thesis for a company now entirely dependent on EQ504 after its prior lead failed Phase 3.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 13 $1.29entry
- T+1 · 6d ago −10.85%α −8.94% · $1.15
- T+5 · 2d ago −17.83%α −9.27% · $1.06
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Equillium filed an S-3 registration statement to register 35,087,717 shares of common stock for resale by selling stockholders who purchased shares and pre-funded warrants in a private placement that closed on October 26, 2026. The company will not receive any proceeds from the resale. The filing is a contractual obligation under a Registration Rights Agreement, not a new capital raise.
Key Facts
- S-3 registers 35,087,717 shares for resale by selling stockholders, including 20,130,457 shares issuable upon exercise of pre-funded warrants
- Shares were sold in a private placement at $0.57 per share (common) and $0.5699 per warrant, with aggregate gross proceeds of approximately $50.0 million
- The company will not receive any proceeds from the resale under this prospectus
- Filing is required under a Registration Rights Agreement dated August 12, 2025
- As of September 30, 2026, the company had $53.3 million in cash and cash equivalents
Financial Impact
Up to 35.1M shares registered for resale, representing approximately 45% of the 78.4M shares outstanding as of October 30, 2026. The maximum aggregate offering price is estimated at $47.0M based on a reference price of $1.34 per share.
Risk Factors
- Potential selling pressure from up to 35.1M shares being registered for resale
- Pre-funded warrants with a nominal exercise price of $0.0001 could be exercised and sold at any time
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-458652 |
| Document: d934327dexfilingfees.htm | 0001193125-26-458652 |
| Document: d934327dex51.htm | 0001193125-26-458652 |
| Document: d934327dex231.htm | 0001193125-26-458652 |
| Document: d934327dex232.htm | 0001193125-26-458652 |
| Document: 0001193125-26-458652-index-headers.html | 0001193125-26-458652 |
| Document: 0001193125-26-458652-index.html | 0001193125-26-458652 |
| Document: 0001193125-26-458652.txt | 0001193125-26-458652 |
Track record
20 reports on EQ
2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +20.40% at T+60 after the Jun 5, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 20, 20262d ago EFFECT Neutral 4/10 Entry $1.12 Now $1.06 −5.36% settles Nov 23
- Nov 16, 20265d ago SC 13G/A Neutral 3/10 Entry $1.21 to $1.10 Now $1.06 −12.40% ▼ −9.09% −8.79% vs SPY
- Nov 13, 20268d ago SC 13G/A Neutral 2/10 Entry $1.15 to $1.21 Now $1.06 −7.83% ▲ +5.22% +6.23% vs SPY
- Nov 12, 20269d ago S-3 Neutral 4/10 Viewing Entry $1.29 to $1.15 Now $1.06 −17.83% ▼ −10.85% −8.94% vs SPY
- Nov 12, 20269d ago 8-K Neutral 5/10 Entry $1.29 to $1.15 Now $1.06 −17.83% ▼ −10.85% −8.94% vs SPY
- Nov 12, 20269d ago SC 13G/A Neutral 2/10 Entry $1.32 to $1.29 Now $1.06 −19.70% ▼ −2.27% −1.91% vs SPY
- Nov 4, 202617d ago SC 13G/A Neutral 2/10 Entry $1.40 to $1.33 Now $1.06 −24.29% ▼ −5.00% −0.59% vs SPY
- Oct 26, 202626d ago 8-K Bearish 6/10 Entry $1.36 to $1.42 Now $1.06 +22.06% ▼ −4.41% −4.07% vs SPY
- Oct 26, 202626d ago Press Release Neutral 4/10 Entry $1.25 to $1.36 Now $1.06 −15.20% ▲ +8.80% +8.24% vs SPY
- Oct 5, 20266w ago 8-K Neutral 3/10 Entry $1.42 to $1.39 Now $1.06 −25.35% ▼ −2.11% −1.87% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers